Core Viewpoint - Notai Biotech will be subject to other risk warnings and will be suspended from trading for one day starting July 21, following a notice from the China Securities Regulatory Commission regarding administrative penalties [2][12]. Summary by Sections Company Announcement - Notai Biotech announced that it will be subject to other risk warnings starting July 22, with its stock name changing to ST Notai [2][16]. - As of the market close on July 18, Notai Biotech's stock price was 40.98 yuan per share, with a total market value of 12.95 billion yuan [4]. Regulatory Findings - The administrative penalty notice indicates that Notai Biotech's 2021 annual report contained false records, and the company fabricated significant false content in its public offering documents [8][11]. - Specifically, in December 2021, Notai Biotech transferred drug technology and licensing rights to Zhejiang Huabei Pharmaceutical Co., confirming business income of 30 million yuan, which was later found to be inflated [10]. Financial Impact - The China Securities Regulatory Commission noted that the transaction with Zhejiang Huabei resulted in an inflated operating income of 30 million yuan and an inflated total profit of 25.9516 million yuan, accounting for 20.64% of the reported profit for that period [10][11]. - Notai Biotech is facing a penalty of 47.4 million yuan and warnings for its actual controller and former director, totaling 28.8 million yuan in fines for related personnel [11]. Future Outlook - Notai Biotech's stock will not enter the risk warning board during the warning period, and the stock price fluctuation limit remains at 20% [16]. - The company projected a net profit of 300 million to 330 million yuan for the first half of 2025, representing a year-on-year growth of 32.06% to 45.27% [16].

Core Viewpoint - Langyuan Co., Ltd. has been penalized for false records in its annual report, leading to a change in its stock name to "ST Langyuan" and a one-day trading suspension [1][3]. Summary by Sections Company Actions - Langyuan Co., Ltd. disclosed that its 2019 annual report and subsequent correction announcement contained false records, resulting in a one-day stock suspension starting March 24, with trading resuming on March 25 under the new name "ST Langyuan" [1][3]. Financial Misstatements - The company acquired 51% of Guangdong Youshi United Holdings Group Co., Ltd. in December 2018, which was included in its consolidated financial statements. In 2019, Guangdong Youshi inflated revenue, costs, and profits through fictitious contracts, leading to an overstatement of Langyuan's 2019 revenue by 52.51 million, costs by 34.94 million, and total profit by 18.16 million, representing 9.03%, 7.94%, and 43.02% of the respective reported figures [1][2]. Regulatory Actions - The Shandong Securities Regulatory Bureau issued a warning and proposed a fine of 5 million for Langyuan Co., Ltd. for the violations. Key executives received individual fines and warnings, with the former general manager facing a 10-year market ban and the former chairman facing a 5-year ban [2].